• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Surgery Classics

The EVAR I trial: Endovascular vs. open abdominal aortic aneurysm repair [Classics Series]

byAndrew Cheung, MD MBA
June 23, 2013
in Surgery Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. The EVAR I trial compared the safety and efficacy of endovascular and open abdominal aortic aneurysm repair

2. There were no significant differences in all-cause mortality between the two groups.

3. The endovascular group experienced significantly higher rates of graft-related complications and reinterventions.

Original Date of Publication: May 20, 2010

The Endovascular Aneurysm Repair (EVAR) trials were randomized controlled trials conducted to explore the safety and efficacy of repairing abdominal aortic aneurysms using endovascular methods. Two trials were conducted simultaneously and published in the same issue of The New England Journal of Medicine.

RELATED REPORTS

Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension

Oral semaglutide reduces cardiovascular event rates in high-risk patients

Pulsed field ablation noninferior to cryoablation for reducing paroxysmal atrial fibrillation recurrence

Study Rundown: Endovascular aortic aneurysm repair was first introduced in the late 1980s as an alternative for people considered unfit for open surgery. Several randomized controlled trials have demonstrated benefits of endovascular repair with regards to 30-day mortality, and it has become increasingly used to manage patients with abdominal aortic aneurysm. There was, however, a paucity of data with regards to the long-term follow-up of endovascular repairs. The EVAR I trial was a landmark study that compared mortality and graft-related complication/reintervention rates in patients who had undergone endovascular and open aortic aneurysm repairs.

There were no significant differences between the two groups in terms of all-cause mortality. While early aneurysm-related mortality (i.e., 0-6 months after repair) was significantly lower in the endovascular repair group, this trend reversed in the longer run. More than 4 years after the repair, the endovascular repair group had significantly higher aneurysm-related mortality than the open group. Moreover, there were significantly higher rates of graft-related complications and reinterventions in the endovascular repair group.

Please click to read study in NEJM

In-Depth [randomized, controlled study]: The EVAR I trial, originally published in 2010 in NEJM, compared endovascular and open methods for abdominal aortic aneurysm repair. The trial was supported by the National Institute for Health Research of the United Kingdom (UK). Patients were eligible for the trial if they were at least 60 years of age, had an abdominal aortic aneurysm with a diameter of at least 5.5 cm on computed tomography, and were anatomically and clinically suitable for either endovascular or open repair. Eligible participants were then randomized to receive either endovascular or open aneurysm repair. The primary outcome was all-cause mortality, while other outcomes were aneurysm-related mortality, graft-related complications, and graft-related reinterventions.

A total of 1,252 patients were recruited for the trial from 37 hospitals across the UK. Approximately 90.7% of the study participants were male. There were no significant differences between the two groups in all-cause mortality at any timepoint. With regards to aneurysm-related mortality, there were significantly fewer deaths in the endovascular repair group until 6 months after the repair (adjusted HR 0.47; 95% CI 0.23-0.93), though this difference was not observed 6 months to 4 years after the repair. More than 4 years after the repair, there were significantly more aneurysm-related deaths in the endovascular groups compared to the open repair group (adjusted HR 4.85; 95% CI 1.04-22.72). There were significantly higher rates of graft-related complications and reinterventions in the endovascular repair group compared to the open group.

By Adrienne Cheung, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: aneurysmcardiologyEndovascularEVAR
Previous Post

2 Minute Medicine Rewind: June 1 – June 9

Next Post

Elevated inflammatory biomarkers linked with increased risk of COPD exacerbations

RelatedReports

Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Cardiology

Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension

June 5, 2025
Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Oral semaglutide reduces cardiovascular event rates in high-risk patients

June 5, 2025
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Pulsed field ablation noninferior to cryoablation for reducing paroxysmal atrial fibrillation recurrence

May 30, 2025
Separate panels of microRNAs may aid in early detection of pancreatic cancer
Cardiology

Lepodisiran, a long-duration small interfering RNA, reduces lipoprotein(a) levels

May 30, 2025
Next Post
Varenicline reduces post-quit smoking relapses

Elevated inflammatory biomarkers linked with increased risk of COPD exacerbations

A marker of aggressive liver cancer and potential therapeutic target identified

A marker of aggressive liver cancer and potential therapeutic target identified

On-demand inhalation treatment for bronchiolitis is superior to fixed schedule treatment

On-demand inhalation treatment for bronchiolitis is superior to fixed schedule treatment

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis
  • Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
  • Oral semaglutide reduces cardiovascular event rates in high-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.